In the past week, TARA stock has gone up by 12.94%, with a monthly decline of -9.86% and a quarterly plunge of -17.95%. The volatility ratio for the week is 7.44%, and the volatility levels for the last 30 days are 7.43% for Protara Therapeutics Inc The simple moving average for the past 20 days is -1.53% for TARA’s stock, with a -27.56% simple moving average for the past 200 days.
Is It Worth Investing in Protara Therapeutics Inc (NASDAQ: TARA) Right Now?
Additionally, the 36-month beta value for TARA is 1.83. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TARA is 18.41M and currently, short sellers hold a 11.11% ratio of that float. The average trading volume of TARA on September 19, 2024 was 170.16K shares.
TARA) stock’s latest price update
Protara Therapeutics Inc (NASDAQ: TARA)’s stock price has gone rise by 5.49 in comparison to its previous close of 1.82, however, the company has experienced a 12.94% increase in its stock price over the last five trading days. globenewswire.com reported 2024-09-09 that NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced completion of the first cohort of the Phase 2 STARBORN-1 trial evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of pediatric patients with lymphatic malformations (LMs). Enrollment is now underway in additional cohorts.
Analysts’ Opinion of TARA
Many brokerage firms have already submitted their reports for TARA stocks, with Guggenheim repeating the rating for TARA by listing it as a “Buy.” The predicted price for TARA in the upcoming period, according to Guggenheim is $22 based on the research report published on July 10, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see TARA reach a price target of $40. The rating they have provided for TARA stocks is “Buy” according to the report published on June 04th, 2021.
Oppenheimer gave a rating of “Outperform” to TARA, setting the target price at $43 in the report published on February 17th of the previous year.
TARA Trading at -7.81% from the 50-Day Moving Average
After a stumble in the market that brought TARA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.36% of loss for the given period.
Volatility was left at 7.43%, however, over the last 30 days, the volatility rate increased by 7.44%, as shares sank -12.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.86% lower at present.
During the last 5 trading sessions, TARA rose by +12.94%, which changed the moving average for the period of 200-days by +32.41% in comparison to the 20-day moving average, which settled at $1.9358. In addition, Protara Therapeutics Inc saw 2.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TARA starting from Opaleye Management Inc., who sale 126,301 shares at the price of $1.71 back on Sep 12 ’24. After this action, Opaleye Management Inc. now owns 45,000 shares of Protara Therapeutics Inc, valued at $215,836 using the latest closing price.
Opaleye Management Inc., the 10% Owner of Protara Therapeutics Inc, sale 32,600 shares at $1.71 during a trade that took place back on Sep 11 ’24, which means that Opaleye Management Inc. is holding 51,500 shares at $55,880 based on the most recent closing price.
Stock Fundamentals for TARA
Current profitability levels for the company are sitting at:
- -36.63 for the present operating margin
- 0.69 for the gross margin
The net margin for Protara Therapeutics Inc stands at -33.68. The total capital return value is set at -0.46. Equity return is now at value -45.90, with -41.35 for asset returns.
Based on Protara Therapeutics Inc (TARA), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -6.69. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -64.41.
Currently, EBITDA for the company is -43.27 million with net debt to EBITDA at 1.92. When we switch over and look at the enterprise to sales, we see a ratio of -37.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.33.
Conclusion
In conclusion, Protara Therapeutics Inc (TARA) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
